𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Safety of extended treatment with sapropterin dihydrochloride in patients with phenylketonuria: Results of a phase 3b study

✍ Scribed by Barbara K. Burton; Maria Nowacka; Julia B. Hennermann; Mark Lipson; Dorothy K. Grange; Anupam Chakrapani; Friedrich Trefz; Alex Dorenbaum; Michael Imperiale; Sun Sook Kim; Paul M. Fernhoff


Book ID
116989324
Publisher
Elsevier Science
Year
2011
Tongue
English
Weight
290 KB
Volume
103
Category
Article
ISSN
1096-7192

No coin nor oath required. For personal study only.


πŸ“œ SIMILAR VOLUMES


Safety and efficacy of 22 weeks of treat
✍ Phillip Lee; Eileen P. Treacy; Eric Crombez; Melissa Wasserstein; Lewis Waber; J πŸ“‚ Article πŸ“… 2008 πŸ› John Wiley and Sons 🌐 English βš– 115 KB πŸ‘ 2 views

## Abstract Phenylketonuria (PKU) is an inherited metabolic disease characterized by phenylalanine (Phe) accumulation, which can lead to neurocognitive and neuromotor impairment. Sapropterin dihydrochloride, an FDA‐approved synthetic formulation of tetrahydrobiopterin (6R‐BH4, herein referred to as